Bancel Stephane's Form 4 filing
Moderna, Inc. (MRNA) · filed Feb 4, 2022
- Accession no.
- 0001127602-22-003346
- Filed
- Feb 4, 2022
- Trade date
- Feb 2-3, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $3.19M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bancel StephaneCIK 0001443340 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2022 | Common Stock | SSaleDisposed | −9,000 | $170.89 | −$1,538,010 | 5,727,535 | Direct | |
| Feb 2, 2022 | Common Stock | GGiftDisposed | −4,000 | –F3 | – | 5,723,535 | Direct | |
| Feb 3, 2022 | Common Stock | SSaleDisposed | −10,000 | $165.00 | −$1,650,000 | 7,034,880 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The reported disposition represents a bona fide charitable gift made by the reporting person.
Referenced by the price of 1 transaction in Table I.